Aromasin
Trovati 8 articoli
- Bone loss in breast cancer survivors: antitumor drugs aren't the only culprits
- Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss. A new study has found that anticancer drugs aren't the only culprits. Among 64 breast cancer patients referred to a bone health clinic, 78 percent had at least one other cause of b... (Leggi Articolo)
- Postmenopausal women: aromatase inhibitors are more effective in preventing breast cancer than Tamoxifen
- Two separate meta-analyses of clinical trials that tested Tamoxifen ( Nolvadex ) against aromatase inhibitors in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Patients usin... (Leggi Articolo)
- Aromatase inhibitors linked to increase in survival in advanced breast cancer
- Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies. In addition, aromatase inhib... (Leggi Articolo)
- Better survival seen for early breast cancer patients switched from Tamoxifen to Exemestane
- Hormone sensitive postmenopausal early breast cancer patients who switched to Exemestane ( Aromasin ) after 2 to 3 years of Tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on Tamoxifen for a full 5 years of therapy, acco... (Leggi Articolo)
- Better survival seen for early breast cancer patients switched from Tamoxifen to Exemestane
- Hormone sensitive postmenopausal early breast cancer patients who switched to Exemestane ( Aromasin ) after 2 to 3 years of Tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on Tamoxifen for a full 5 years of therapy, acco... (Leggi Articolo)
- Early breast cancer: better survival seen for patients switched from Tamoxifen to Exemestane
- New data from the Intergroup Exemestane Study ( IES ) showed that hormone sensitive postmenopausal early breast cancer patients who switched to Exemestane ( Aromasin ) after 2 to 3 years of Tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patien... (Leggi Articolo)
- Vaginal oestrogen linked to mammary carcinoma
- Breast tumor specialists cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, Anastrozole ( Arimidex ), Letrozole ( Femara ) and Exemestane ( Aromasin ). Their concerns follow findings from the first st... (Leggi Articolo)
- FDA approves Aromasin for adjuvant treatment of early breast cancer in postmenopausal women
- The FDA ( U.S. Food and Drug Administration ) approved Aromasin ( Exemestane tablets ) for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two-to-three years of Tamoxifen for a completion of five consecutive years of adjuvant hormonal thera... (Leggi Articolo)
